Serum levels of HSP90 in the continuum of breast ductal and lobular lesions

In Vivo

Volumn 25, Issue 4, 2011, Pages 669-672

  Zagouri, Flora ^a   Sergentanis, Theodoros N ^a   Xeni, Provatopoulou ^b   Kalogera, Eleni ^b   Chrysikos, Dimosthenis ^a   Lymperi, Maria ^a   Papadimitriou, Christos A ^a   Zografos, Eleni ^a   Bletsa, Garifallia ^a   Kalles, Vasileios S ^a   Zografos, George C ^a   Antonia, Gounaris ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b Hellenic Anticancer Institute   (Greece)

Author keywords

Atypical ductal hyperplasia; Breast cancer; Ductal carcinoma in situ; HSP90; Lobular neoplasia; Serum

Indexed keywords

HEAT SHOCK PROTEIN 90;

ADULT; ARTICLE; ATYPICAL DUCTAL HYPERPLASIA; BREAST CANCER; BREAST LESION; COMPARATIVE STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; INFILTRATIVE LOBULAR CARCINOMA; INTRADUCTAL CARCINOMA; INVASIVE DUCTAL CARCINOMA; LOBULAR NEOPLASIA; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL;

EID: 79960637601     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Lai BT, Chin NW, Stanek AE, Keh W and Lanks KW: Quantitation and intracellular localization of the 85k heat-shock protein by using monoclonal and polyclonal antibodies. Mol Cell Biol 4: 2802-2810, 1984. (Pubitemid 15113620)
2. Whitley D, Goldberg SP and Jordan WD: Heat shock proteins: a review of the molecular chaperones. J Vasc Surg 29: 748-751, 1999. (Pubitemid 29181256)
3. Beliakoff J and Whitesell L: HSP90 an emerging target for breast cancer therapy. Anticancer Drugs 15: 651-662, 2004. (Pubitemid 39099914)
4. Conroy SE and Latchman DS: Do heat-shock proteins have a role in breast cancer? Br J Cancer 74: 717-721, 1996.
5. Yano M, Naito Z, Tanaka S and Asano G: Expression and roles of heat shock proteins in human breast cancer. Jpn J Cancer Res 87: 908-915, 1996. (Pubitemid 26328915)
6. Yano M, Naito Z, Yokoyama M, Shiraki Y, Ishiwata T, Inokuchi M and Asano G: Expression of HSP90 and cyclin D1 in human breast cancer. Cancer Lett 137: 45-51, 1999. (Pubitemid 29179495)
7. Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL and Kluger HM: High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 67: 2932-2937, 2007. (Pubitemid 46724827)
8. Zagouri F, Sergentanis TN, Nonni A, Papadimitriou CA, Michalopoulos NV, Domeyer P, Theodoropoulos G, Lazaris A, Patsouris E, Zogafos E, Pazaiti A and Zografos GC: HSP90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions. BMC Cancer 10: 353, 2010.
9. Zagouri F, Sergentanis T, Nonni A, Papadimitriou C, Pazaiti A, Michalopoulos N, Safioleas P, Lazaris A, Theodoropoulos G, Patsouris E and Zografos G: Decreased HSP90 expression in infiltrative lobular carcinoma: an immunohistochemical study. BMC Cancer 10: 409, 2010.
10. Zagouri F, Nonni A, Sergentanis TN, Papadimitriou CA, Michalopoulos NV, Lazaris AC, Patsouris E and Zografos GC: Heat shock protein 90 in lobular neoplasia of the breast. BMC Cancer 8: 312, 2008.
11. Kim LS, Lee HS, Choi JW, Kang HJ and Price JE: The role of heat shock protein 90/70 as potential molecular therapeutic targets in breast cancer. In: Proceedings. of the 90th Annual Meeting of the American Association for Cancer Research: 16-20 April 2005; Anaheim, CA. Philadelphia, PA; AACR: 2346, 2005.
12. Miyata Y: HSP90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 11: 1131-1138, 2005.
13. Bagatell R and Whitesell L: Altered HSP90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 3: 1021-1030, 2004. (Pubitemid 39199597)
14. Sõti C, Nagy E, Giricz Z, Vígh L, Csermely P and Ferdinandy P: Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 146: 769-780, 2005. (Pubitemid 41622243)
15. Workman P, Burrows F, Neckers L and Rosen N: Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 1113: 202-216, 2007. (Pubitemid 350015011)
16. Holmes JL, Sharp SY, Hobbs S and Workman P: Silencing of HSP90 co-chaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17- demethoxygeldanamycin. Cancer Res 68: 1188-1197, 2008.
17. Zagouri F, Sergentanis TN and Zografos GC: Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol 5: 57, 2007.
18. Van de Vijver MJ and Peterse H: The diagnosis and management of pre-invasive breast disease: pathological diagnosis-problems with existing classifications. Breast Cancer Res 5: 269, 2003.
19. Purushotham AD: The diagnosis and management of pre-invasive breast disease: problems associated with management of pre-invasive lesions. Breast Cancer Res 5: 309-312, 2003.
20. Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, Riethdorf L, Brinkschmidt C, Dockhorn-Dworniczak B and Boecker W: Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol 187: 396-402, 1999. (Pubitemid 29118269)
21. Dupont WD Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312: 146-151, 1985.
22. Allred DC, Mohsin SK and Fuqua SA: Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8: 47-61, 2001. (Pubitemid 32520253)
23. Moinfar F, Man YG, Bratthauer GL, Ratschek M, Tavassoli FA: Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ('clinging ductal carcinoma in situ'): a simulator of normal mammary epithelium. Cancer 88: 2072-2081, 2000.
24. Schreer I and Luttges J: Precursor lesions of invasive breast cancer. Eur J Radiol 54: 62-71, 2005. (Pubitemid 40417473)
25. Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand JC, Fourquet A and Pouillart P: Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77: 113-120, 1996.
26. Whitesell L and Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772, 2005.
27. Sun Y, Zang Z, Xu X, Zhang Z, Zhong L, Zan W, Zhao Y and Sun L: Differential proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry. Int J Mol Sci 114: 1423-1433, 2010.
28. Dakappagari N, Neely L, Tangri S, Lundgren K, Hipolito L, Estrellado A, Burrows F and Zhang H: An investigation into the potential use of serum HSP70 as a novel tumour biomarker for HSP90 inhibitors. Biomarkers 15: 31-38, 2010.
29. Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, Zhang L, Biamonte M, Brekken J, Lundgren K and Burrows F: Identification of new biomarkers for clinical trials of HSP90 inhibitors. Mol Cancer Ther 5: 1256-1264, 2006. (Pubitemid 43881318)